Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc., trading under the ticker TVGN, is a clinical-stage biopharmaceutical company focused on developing off-the-shelf T-cell immunotherapies targeting infectious diseases and oncology. The company became publicly listed through a SPAC business combination and filed its annual 10-K with the SEC on April 29, 2024, covering fiscal year 2023 — one of its first full reporting periods as a public entity. Operating in the biotechnology and immunotherapy sector, Tevogen Bio is advancing a pipeline built around proprietary cytotoxic T lymphocyte platforms designed to address unmet medical needs at scale. Sign up for full SPAC data, filings history, and deal analytics on SpacDesk.